Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after ...
The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...
FDA proposes using a well-supported mechanistic rationale plus natural history comparators to generate substantial evidence when randomized trials are infeasible for ultra-rare populations.
Following this weekend’s strong opening for Goat, Sony Pictures Animation will open its next original feature toon, Buds, on Wednesday, Dec. 22, 2027. The only other movie dated for Dec. 22 is a ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
A stem cell transplant usually requires you to stay in the hospital for weeks and get frequent checkups for months after you go home. Close monitoring lets your health care team support your recovery ...
What Is Yartemlea, and Why Does It Matter? Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic ...
Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for ...
It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...
The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results